Freedom EVO® Cell Permeability

Our Cell Permeability platform has been designed to include all of the components necessary to perform compound permeability assays across either cell or artificial membrane barriers. The Freedom EVO workstation has been configured for Caco-2 or Madin-Darby canine kidney (MDCK) cell assays, used to predict the intestinal permeability potential of a compound. An example of data generated is shown in table 1. The Cell Permeability platform can also be routinely used for active transport and/or compound efflux measurements, and for artificial membrane permeability assays in place of the cell-based systems, for example, for running parallel artificial membrane permeability assays (PAMPAs). An example of data generated on a Freedom EVO is shown in figure 1.

Table 1 Comparison of manual and automated compound permeability assays

Permeability rates (Papp) were determined radiometrically for both Caco-2 and MDCK cell lines. Each drug was run in replicates of six wells per cell line, transepithelial electrical resistance (TEER) measurements (not shown) before drug analysis indicated an integral cell monolayer, and Lucifer yellow post-processing indicated that the cell monolayer was not disturbed during processing (all samples ≥98%, data not shown).
Kellard L, Engelstein M. 2007. Journal of the Association for Laboratory Automation
(JALA), 12:104–109.

Figure 1 Parallel artificial membrane permeability assay (PAMPA) 

Comparison of a set of Double-Sink™ PAMPA measurements on new PAMPA EvolutionPLUS system against values from pION's database. The assay conditions were pH 6.2 in donor, 30 minutes incubation and Gut-Box™ stirring at 40 µm setting
Data courtesy of pION INC, Woburn, MA, USA.